ADAP has 36-month beta value of 2.31. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 1 as “sell.”
The public float for ADAP is 226.10M, and currently, short sellers hold a 2.50% ratio of that float. The average trading volume of ADAP on July 24, 2024 was 1.61M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ADAP) stock’s latest price update
The stock of Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) has increased by 4.88 when compared to last closing price of 1.23. Despite this, the company has experienced a 2.38% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2024-07-03 that Adaptimmune Therapeutics is focused on late-stage development of cell therapy for cancer, particularly in sarcoma management. Pipeline updates include progress on afami-cel for soft tissue sarcomas and lete-cel for synovial sarcoma. Financially, ADAP has a cash runway of around 3 quarters, with potential resources from collaborations and agreements extending it further.
ADAP’s Market Performance
Adaptimmune Therapeutics Plc ADR (ADAP) has seen a 2.38% rise in stock performance for the week, with a 46.49% gain in the past month and a 13.16% surge in the past quarter. The volatility ratio for the week is 7.75%, and the volatility levels for the past 30 days are at 9.24% for ADAP. The simple moving average for the past 20 days is 14.02% for ADAP’s stock, with a 32.30% simple moving average for the past 200 days.
Analysts’ Opinion of ADAP
Many brokerage firms have already submitted their reports for ADAP stocks, with Scotiabank repeating the rating for ADAP by listing it as a “Sector Outperform.” The predicted price for ADAP in the upcoming period, according to Scotiabank is $3.15 based on the research report published on May 30, 2024 of the current year 2024.
Bryan Garnier, on the other hand, stated in their research note that they expect to see ADAP reach a price target of $3.60. The rating they have provided for ADAP stocks is “Buy” according to the report published on March 24th, 2023.
Guggenheim gave a rating of “Buy” to ADAP, setting the target price at $5 in the report published on January 03rd of the previous year.
ADAP Trading at 19.62% from the 50-Day Moving Average
After a stumble in the market that brought ADAP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.07% of loss for the given period.
Volatility was left at 9.24%, however, over the last 30 days, the volatility rate increased by 7.75%, as shares surge +46.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.21% upper at present.
During the last 5 trading sessions, ADAP rose by +0.63%, which changed the moving average for the period of 200-days by +76.10% in comparison to the 20-day moving average, which settled at $1.1515. In addition, Adaptimmune Therapeutics Plc ADR saw 62.67% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADAP starting from Piccina Cintia, who sale 24,531 shares at the price of $0.93 back on Jun 18 ’24. After this action, Piccina Cintia now owns 38,293 shares of Adaptimmune Therapeutics Plc ADR, valued at $22,814 using the latest closing price.
Rawcliffe Adrian, the Chief Executive Officer of Adaptimmune Therapeutics Plc ADR, sale 30,080 shares at $0.67 during a trade that took place back on Jan 17 ’24, which means that Rawcliffe Adrian is holding 44,848 shares at $20,244 based on the most recent closing price.
Stock Fundamentals for ADAP
Current profitability levels for the company are sitting at:
- -10.59 for the present operating margin
- 0.41 for the gross margin
The net margin for Adaptimmune Therapeutics Plc ADR stands at -8.92. The total capital return value is set at -1.02. Equity return is now at value -302.27, with -59.92 for asset returns.
Based on Adaptimmune Therapeutics Plc ADR (ADAP), the company’s capital structure generated 0.49 points at debt to capital in total, while cash flow to debt ratio is standing at -5.72. The debt to equity ratio resting at 0.97. The interest coverage ratio of the stock is -38894.97.
Currently, EBITDA for the company is -127.91 million with net debt to EBITDA at 0.55. When we switch over and look at the enterprise to sales, we see a ratio of 11.51. The receivables turnover for the company is 0.64for trailing twelve months and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.81.
Conclusion
To put it simply, Adaptimmune Therapeutics Plc ADR (ADAP) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
